slit1 protein Search Results


N/A
Human SLIT1 Protein Lysate 20ug from Innovative Research is provided as a Lyophilized powder. This is a Recombinant Protein Lysate produced in HEK293T cells. This protein lysate can be reconsituted using SDS Sample Buffer. Once
  Buy from Supplier

92
R&D Systems recombinant mouse slit protein
Functional Validation of Genetic Reagents and Test of Interaction between Robo and Notch Signaling, Related to , , and (A and B) Validation of dnRobo and myrRobo as dominant-negative and constitutively active for Robo signaling, respectively. In (A), growth cone collapse assay of growing axons from explants of embryonic mouse retinas, electroporated to express Gfp or dnRobo and exposed to <t>recombinant</t> Slit protein or vehicle solution. Failure of response to Slit upon dnRobo-overexpression demonstrates its dominant-negative effect (n = 44-58 growth cones per group, 3 independent experiments). In (B), branching assay of growing axons from single neurons of embryonic rat dorsal root ganglion, overexpressing Gfp alone or with myrRobo constructs as indicated. Exuberant axonal branching typically elicited by Slit-Robo signaling occurs in myrRobo-expressing neurons in the absence of Slit, demonstrating constitutive activation of Robo signaling (n = 5-10 neurons per group). (C–F) Validation of crispr constructs for disruption of Dll1 in mouse and human. (C) Top, sequence of the gRNA targeting mouse Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the mDll1 coding sequence (gray bar). Bottom, validation of Crispr-mediated editing of the mDll1 locus upon electroporation with gDll1 plus Cas9, but not with Cas9 alone. Different lanes correspond to independent electroporated embryos. M, molecular weight marker. Arrow indicates 1,025 bp amplicon, arrowheads indicate the products of PCR amplicon digestion by Syrveyor Nuclease (656 + 368 bp), absent in the Cas9-alone lanes. (D) Left, sequence of the gRNA targeting human Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the hDll1 coding sequence (gray bar). Right, chromograms for genome sequence validation of Crispr-mediated editing of the hDll1 locus upon electroporation of cerebral organoid with gDll1 plus Cas9. A 270bp fragment was inserted at position 54 of the coding sequence, introducing a STOP codon in position 76. (E and F) Effect of electroporating crDll1 in NCx (green cells) on the abundance of Dll1 protein (red). Details are examples VZ cells loosing Dll1 protein (arrowheads) from the cell surface upon crDll1 (n = 3 embryos per group). (G–K) Antibody stain for GFP and Robo1 or Dll1 in NCx at E13.5 upon electroporation of the indicated plasmid combinations at E12.5, and quantifications (paired t test). Arrowheads indicate area of increased Robo (n = 3 embryos per group). Values are mean + SEM; paired or independent samples t tests; ∗ p < 0.05; ns, not significant. Scale bars: 30 μm (E), 50 μm (G and H).
Recombinant Mouse Slit Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/Recombinant+Mouse+Slit1+Protein%2C+CF/pmc06063992-679-4-8
Average 92 stars, based on 1 article reviews
recombinant mouse slit protein - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

94
Proteintech slit3
Osteoblasts respond to PTH treatment with increased <t>Slit3</t> transcription and translation. mRNA expression of the Slit3 in the endplate tissue of WT young mice treated with Veh and aged mice treated with Veh or PTH for 1 month ( a ), and WT LSI mice treated with veh or PTH for 2 months ( b ) ( n = 3, one-way ANOVA with Tukey’s multiple comparisons test). c mRNA expression of the Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and subsequently treated with Veh or PTH at different doses for 3 days ( n = 3, t -test). d , e Protein expression level of Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and treated with Veh (PBS) or PTH for 3 days. ( n = 3, t -test). Representative images ( f ) and quantification ( g ) of IF staining of PGP9.5 positive primary DRG neuron fibers crossing the microgroove barrier (microfluid assay) cultured in condition medium (CM), CM + PTH, CM + PTH plus mouse Slit3 antibody (1 µg/mL), or CM + Veh (1X PBS) plus human recombinant Slit3 (1.25 µg/mL) for 1 week. Representative images showing co-immunostaining for OCN (green) and Slit3 (red) in the lumbar spine sections and quantitative analysis of number of Slit3 + cells in trabecular bone (TB) and endplate (EP) of aged mice ( h – j ) and PPR OCN −/− LSI mice ( k – m ) treated with PTH or Veh for 2 months. Scale bar: 100 µm. ( n ≥ 5, t -test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001
Slit3, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/SLIT1+Fusion+Protein/pmc12827982-253-44-59
Average 94 stars, based on 1 article reviews
slit3 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

92
R&D Systems recombinant slit1
Figure 2. <t>Slit1</t> Enables Netrin-1 Attraction by Activating the Robo1 Receptor
Recombinant Slit1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/Recombinant+Mouse+Slit1+Protein%2C+CF/pm24560577-219-0-4
Average 92 stars, based on 1 article reviews
recombinant slit1 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

94
R&D Systems human slit1
Effect of <t>SLIT1</t> supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.
Human Slit1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/Recombinant+Human+Slit1+Protein%2C+CF/pmc05711798-90-32-34
Average 94 stars, based on 1 article reviews
human slit1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
R&D Systems slit 1
Effect of <t>SLIT1</t> supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.
Slit 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/Recombinant+Human+Slit1+Protein%2C+CF/pmc08143016-71-20-21
Average 93 stars, based on 1 article reviews
slit 1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
SLIT2 LTD slit family genes slit1
Effect of <t>SLIT1</t> supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.
Slit Family Genes Slit1, supplied by SLIT2 LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slit1+protein/slit1+protein/pm35131473-321-10-15
Average 90 stars, based on 1 article reviews
slit family genes slit1 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

N/A
The Recombinant Mouse Slit1 Protein from R D Systems is derived from CHO The Recombinant Mouse Slit1 Protein has been validated for the following applications Bioactivity
  Buy from Supplier

N/A
Recombinant Mouse SLIT1 full length or partial length protein was expressed.http://www.creativebiomart.net/Recombinant-Mouse-SLIT1-Protein-446820.htm
  Buy from Supplier

N/A
Recombinant Human Slit1 (aa 1129-1534) Protein, CF
  Buy from Supplier

N/A
Recombinant Human SLIT1 (Accession # NP_003052) Met1-Gln915, fused with a C-terminal 6-His tag, was produced in Chinese Hamster Ovary cell line, CHO-derived.http://www.creativebiomart.net/description_437194_12.htm
  Buy from Supplier

N/A
Recombinant Rat SLIT1 full length or partial length protein was expressed.http://www.creativebiomart.net/Recombinant-Rat-SLIT1-Protein-454425.htm
  Buy from Supplier

Image Search Results


Functional Validation of Genetic Reagents and Test of Interaction between Robo and Notch Signaling, Related to , , and (A and B) Validation of dnRobo and myrRobo as dominant-negative and constitutively active for Robo signaling, respectively. In (A), growth cone collapse assay of growing axons from explants of embryonic mouse retinas, electroporated to express Gfp or dnRobo and exposed to recombinant Slit protein or vehicle solution. Failure of response to Slit upon dnRobo-overexpression demonstrates its dominant-negative effect (n = 44-58 growth cones per group, 3 independent experiments). In (B), branching assay of growing axons from single neurons of embryonic rat dorsal root ganglion, overexpressing Gfp alone or with myrRobo constructs as indicated. Exuberant axonal branching typically elicited by Slit-Robo signaling occurs in myrRobo-expressing neurons in the absence of Slit, demonstrating constitutive activation of Robo signaling (n = 5-10 neurons per group). (C–F) Validation of crispr constructs for disruption of Dll1 in mouse and human. (C) Top, sequence of the gRNA targeting mouse Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the mDll1 coding sequence (gray bar). Bottom, validation of Crispr-mediated editing of the mDll1 locus upon electroporation with gDll1 plus Cas9, but not with Cas9 alone. Different lanes correspond to independent electroporated embryos. M, molecular weight marker. Arrow indicates 1,025 bp amplicon, arrowheads indicate the products of PCR amplicon digestion by Syrveyor Nuclease (656 + 368 bp), absent in the Cas9-alone lanes. (D) Left, sequence of the gRNA targeting human Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the hDll1 coding sequence (gray bar). Right, chromograms for genome sequence validation of Crispr-mediated editing of the hDll1 locus upon electroporation of cerebral organoid with gDll1 plus Cas9. A 270bp fragment was inserted at position 54 of the coding sequence, introducing a STOP codon in position 76. (E and F) Effect of electroporating crDll1 in NCx (green cells) on the abundance of Dll1 protein (red). Details are examples VZ cells loosing Dll1 protein (arrowheads) from the cell surface upon crDll1 (n = 3 embryos per group). (G–K) Antibody stain for GFP and Robo1 or Dll1 in NCx at E13.5 upon electroporation of the indicated plasmid combinations at E12.5, and quantifications (paired t test). Arrowheads indicate area of increased Robo (n = 3 embryos per group). Values are mean + SEM; paired or independent samples t tests; ∗ p < 0.05; ns, not significant. Scale bars: 30 μm (E), 50 μm (G and H).

Journal: Cell

Article Title: Evolution of Cortical Neurogenesis in Amniotes Controlled by Robo Signaling Levels

doi: 10.1016/j.cell.2018.06.007

Figure Lengend Snippet: Functional Validation of Genetic Reagents and Test of Interaction between Robo and Notch Signaling, Related to , , and (A and B) Validation of dnRobo and myrRobo as dominant-negative and constitutively active for Robo signaling, respectively. In (A), growth cone collapse assay of growing axons from explants of embryonic mouse retinas, electroporated to express Gfp or dnRobo and exposed to recombinant Slit protein or vehicle solution. Failure of response to Slit upon dnRobo-overexpression demonstrates its dominant-negative effect (n = 44-58 growth cones per group, 3 independent experiments). In (B), branching assay of growing axons from single neurons of embryonic rat dorsal root ganglion, overexpressing Gfp alone or with myrRobo constructs as indicated. Exuberant axonal branching typically elicited by Slit-Robo signaling occurs in myrRobo-expressing neurons in the absence of Slit, demonstrating constitutive activation of Robo signaling (n = 5-10 neurons per group). (C–F) Validation of crispr constructs for disruption of Dll1 in mouse and human. (C) Top, sequence of the gRNA targeting mouse Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the mDll1 coding sequence (gray bar). Bottom, validation of Crispr-mediated editing of the mDll1 locus upon electroporation with gDll1 plus Cas9, but not with Cas9 alone. Different lanes correspond to independent electroporated embryos. M, molecular weight marker. Arrow indicates 1,025 bp amplicon, arrowheads indicate the products of PCR amplicon digestion by Syrveyor Nuclease (656 + 368 bp), absent in the Cas9-alone lanes. (D) Left, sequence of the gRNA targeting human Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the hDll1 coding sequence (gray bar). Right, chromograms for genome sequence validation of Crispr-mediated editing of the hDll1 locus upon electroporation of cerebral organoid with gDll1 plus Cas9. A 270bp fragment was inserted at position 54 of the coding sequence, introducing a STOP codon in position 76. (E and F) Effect of electroporating crDll1 in NCx (green cells) on the abundance of Dll1 protein (red). Details are examples VZ cells loosing Dll1 protein (arrowheads) from the cell surface upon crDll1 (n = 3 embryos per group). (G–K) Antibody stain for GFP and Robo1 or Dll1 in NCx at E13.5 upon electroporation of the indicated plasmid combinations at E12.5, and quantifications (paired t test). Arrowheads indicate area of increased Robo (n = 3 embryos per group). Values are mean + SEM; paired or independent samples t tests; ∗ p < 0.05; ns, not significant. Scale bars: 30 μm (E), 50 μm (G and H).

Article Snippet: After 24h of incubation, recombinant mouse Slit protein (R&D Systems) was added to the medium (250ng/μl) and the explants were fixed 1h later with PFA 2% during 15 min.

Techniques: Functional Assay, Biomarker Discovery, Dominant Negative Mutation, Recombinant, Over Expression, Construct, Expressing, Activation Assay, CRISPR, Disruption, Sequencing, Electroporation, Molecular Weight, Marker, Amplification, Staining, Plasmid Preparation

Osteoblasts respond to PTH treatment with increased Slit3 transcription and translation. mRNA expression of the Slit3 in the endplate tissue of WT young mice treated with Veh and aged mice treated with Veh or PTH for 1 month ( a ), and WT LSI mice treated with veh or PTH for 2 months ( b ) ( n = 3, one-way ANOVA with Tukey’s multiple comparisons test). c mRNA expression of the Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and subsequently treated with Veh or PTH at different doses for 3 days ( n = 3, t -test). d , e Protein expression level of Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and treated with Veh (PBS) or PTH for 3 days. ( n = 3, t -test). Representative images ( f ) and quantification ( g ) of IF staining of PGP9.5 positive primary DRG neuron fibers crossing the microgroove barrier (microfluid assay) cultured in condition medium (CM), CM + PTH, CM + PTH plus mouse Slit3 antibody (1 µg/mL), or CM + Veh (1X PBS) plus human recombinant Slit3 (1.25 µg/mL) for 1 week. Representative images showing co-immunostaining for OCN (green) and Slit3 (red) in the lumbar spine sections and quantitative analysis of number of Slit3 + cells in trabecular bone (TB) and endplate (EP) of aged mice ( h – j ) and PPR OCN −/− LSI mice ( k – m ) treated with PTH or Veh for 2 months. Scale bar: 100 µm. ( n ≥ 5, t -test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Osteoblasts respond to PTH treatment with increased Slit3 transcription and translation. mRNA expression of the Slit3 in the endplate tissue of WT young mice treated with Veh and aged mice treated with Veh or PTH for 1 month ( a ), and WT LSI mice treated with veh or PTH for 2 months ( b ) ( n = 3, one-way ANOVA with Tukey’s multiple comparisons test). c mRNA expression of the Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and subsequently treated with Veh or PTH at different doses for 3 days ( n = 3, t -test). d , e Protein expression level of Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and treated with Veh (PBS) or PTH for 3 days. ( n = 3, t -test). Representative images ( f ) and quantification ( g ) of IF staining of PGP9.5 positive primary DRG neuron fibers crossing the microgroove barrier (microfluid assay) cultured in condition medium (CM), CM + PTH, CM + PTH plus mouse Slit3 antibody (1 µg/mL), or CM + Veh (1X PBS) plus human recombinant Slit3 (1.25 µg/mL) for 1 week. Representative images showing co-immunostaining for OCN (green) and Slit3 (red) in the lumbar spine sections and quantitative analysis of number of Slit3 + cells in trabecular bone (TB) and endplate (EP) of aged mice ( h – j ) and PPR OCN −/− LSI mice ( k – m ) treated with PTH or Veh for 2 months. Scale bar: 100 µm. ( n ≥ 5, t -test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Expressing, Cell Culture, Staining, Recombinant, Immunostaining

Transcriptional mechanism underpinning Slit3 secretion. a mRNA expression levels of Ets1, E47, FoxJ2 , and FoxA2 genes in MC3T3 cells cultured in osteoblast differentiation-inducing medium and treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, t -test). b , c Protein expression level of E47, FoxA2 in MC3T3 cells cultured in stimulated medium and treated with PTH or Veh (PBS) for 3 days ( n = 3, t -test). Representative images depicting E47 IF staining (green) in lumbar vertebral body and endplate sections ( d ), quantitative analysis of the number of E47 + cells in the vertebral body ( e ) and endplate ( f ) of aged mice treated with Veh or PTH ( n = 5, t -tset). Scale bar: 100 µm. Representative images showing FoxA2 IF staining (red) in lumbar vertebral body and endplate sections ( g ), quantitative analysis of the number of FoxA2 + cells in the vertebral body ( h ) and endplate ( i ) of aged mice treated with PTH or vehicle for 2 months ( n = 5, t -tset). Scale bar: 100 µm. j Relative fold enrichment of the E47 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). k Relative fold enrichment of the FoxA2 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Transcriptional mechanism underpinning Slit3 secretion. a mRNA expression levels of Ets1, E47, FoxJ2 , and FoxA2 genes in MC3T3 cells cultured in osteoblast differentiation-inducing medium and treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, t -test). b , c Protein expression level of E47, FoxA2 in MC3T3 cells cultured in stimulated medium and treated with PTH or Veh (PBS) for 3 days ( n = 3, t -test). Representative images depicting E47 IF staining (green) in lumbar vertebral body and endplate sections ( d ), quantitative analysis of the number of E47 + cells in the vertebral body ( e ) and endplate ( f ) of aged mice treated with Veh or PTH ( n = 5, t -tset). Scale bar: 100 µm. Representative images showing FoxA2 IF staining (red) in lumbar vertebral body and endplate sections ( g ), quantitative analysis of the number of FoxA2 + cells in the vertebral body ( h ) and endplate ( i ) of aged mice treated with PTH or vehicle for 2 months ( n = 5, t -tset). Scale bar: 100 µm. j Relative fold enrichment of the E47 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). k Relative fold enrichment of the FoxA2 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Expressing, Cell Culture, Staining, Binding Assay

Efficacy of PTH treatment is diminished in osteoblastic Slit3 knockout mice with spinal degeneration. Vertebral endplate bone structure analyses by micro-CT: bone volume per tissue volume (BV/TV) percentage ( a ), total porosity percentage ( b ), and total pore space ( c ) in Slit3 OCN −/− LSI mice with PTH (40 µg/kg/d) or Veh treatment for 2 months ( n = 7, t -test). Behavior evaluations included pressure tolerance of the lumbar spine assessed via the force threshold ( d ), total distance covered in spontaneous activity in 2 days ( e ), and latency of paw withdrawal post-thermal stimulation ( f ) for Slit3 OCN −/− LSI mice with PTH or Veh treatment for 2 months ( n = 7, t -test). g Western blot analysis of protein expression levels of β3 tubulin, CGRP, PGP9.5 relative to GAPDH in endplate tissue (L3-L5) in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months. ( n = 5). Representative images of PGP9.5 (red) and CGRP (green)-positive fibers ( h ) and quantitative analysis of fiber length in the lumbar vertebral body of Slit3 OCN −/− LSI mice with PTH or Veh treatment ( i , j ) ( n = 5, t -tset). Scale bar: 100 µm. k Western blot analysis of protein expression levels of CGRP in DRG tissue (L1–L2), normalized to GAPDH expression, in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5). Representative IF images showing CGRP-positive (green) neurons in DRG sections ( l ), followed by quantitative analysis of the mean IF intensity for CGRP ( m ) in the DRG of Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5, t -tset). Scale bar: 100 µm

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Efficacy of PTH treatment is diminished in osteoblastic Slit3 knockout mice with spinal degeneration. Vertebral endplate bone structure analyses by micro-CT: bone volume per tissue volume (BV/TV) percentage ( a ), total porosity percentage ( b ), and total pore space ( c ) in Slit3 OCN −/− LSI mice with PTH (40 µg/kg/d) or Veh treatment for 2 months ( n = 7, t -test). Behavior evaluations included pressure tolerance of the lumbar spine assessed via the force threshold ( d ), total distance covered in spontaneous activity in 2 days ( e ), and latency of paw withdrawal post-thermal stimulation ( f ) for Slit3 OCN −/− LSI mice with PTH or Veh treatment for 2 months ( n = 7, t -test). g Western blot analysis of protein expression levels of β3 tubulin, CGRP, PGP9.5 relative to GAPDH in endplate tissue (L3-L5) in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months. ( n = 5). Representative images of PGP9.5 (red) and CGRP (green)-positive fibers ( h ) and quantitative analysis of fiber length in the lumbar vertebral body of Slit3 OCN −/− LSI mice with PTH or Veh treatment ( i , j ) ( n = 5, t -tset). Scale bar: 100 µm. k Western blot analysis of protein expression levels of CGRP in DRG tissue (L1–L2), normalized to GAPDH expression, in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5). Representative IF images showing CGRP-positive (green) neurons in DRG sections ( l ), followed by quantitative analysis of the mean IF intensity for CGRP ( m ) in the DRG of Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5, t -tset). Scale bar: 100 µm

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Knock-Out, Micro-CT, Activity Assay, Western Blot, Expressing

Figure 2. Slit1 Enables Netrin-1 Attraction by Activating the Robo1 Receptor

Journal: Current biology : CB

Article Title: FLRT3 is a Robo1-interacting protein that determines Netrin-1 attraction in developing axons.

doi: 10.1016/j.cub.2014.01.042

Figure Lengend Snippet: Figure 2. Slit1 Enables Netrin-1 Attraction by Activating the Robo1 Receptor

Article Snippet: Recombinant Slit1 (5 nM; R&D Systems), FLRT3-ECD [15] (1 mg/ml), a mouse anti-DCC antibody (AF5 clone; Abcam), or control mouse IgG was (J and K) Robo1+/+ rTCAs grow rostrally as a compact bundle (J), whereas the (L) Quantification of the data represented in (J) and (K). rTCA dispersion at the v tailed Student’s t test. (M) Scheme representing the topographic guidance of rTCAs and iTCAs in t Slit1 and Netrin-1 [21].

Techniques:

Effect of SLIT1 supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: Effect of SLIT1 supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Immunostaining, Control, Real-time Polymerase Chain Reaction, Expressing

Effect of locally sustained release of SLIT1 (5μg/ml) from hydrogels placed in front of the attached OVs. Locally sustained release of SLIT1 using hydrogel does not affect axonal growth of hESC- and hiPSC-derived RGCs (( a ) and ( d ), respectively, magnification 40x). Only a subset of axons is repelled by SLIT1 release (( b ) and ( e ), magnification 100x: squares in ( a ) and ( d ), respectively), while other axons remain unaffected. Filopodia of hESC- and hiPSC-derived RGCs (( c ) and ( f ), respectively) have collapsed in response to SLIT1 release, as evident from phalloidin and GAP43 staining. The assessment from D27 is performed under RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Squares in ( a ) and ( d ) correspond to ( b ) and ( e ), respectively. Scale bars in ( a ) and ( d ), 100 μm. Scale bars in ( b ) and ( e ), 40 μm. Scale bars in ( c ) and ( f ), 10 μm.

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: Effect of locally sustained release of SLIT1 (5μg/ml) from hydrogels placed in front of the attached OVs. Locally sustained release of SLIT1 using hydrogel does not affect axonal growth of hESC- and hiPSC-derived RGCs (( a ) and ( d ), respectively, magnification 40x). Only a subset of axons is repelled by SLIT1 release (( b ) and ( e ), magnification 100x: squares in ( a ) and ( d ), respectively), while other axons remain unaffected. Filopodia of hESC- and hiPSC-derived RGCs (( c ) and ( f ), respectively) have collapsed in response to SLIT1 release, as evident from phalloidin and GAP43 staining. The assessment from D27 is performed under RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Squares in ( a ) and ( d ) correspond to ( b ) and ( e ), respectively. Scale bars in ( a ) and ( d ), 100 μm. Scale bars in ( b ) and ( e ), 40 μm. Scale bars in ( c ) and ( f ), 10 μm.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Staining

The effect of focally sustained release of SLIT1 on pathfinding of axons derived from hESC- and hiPSC-derived RGCs. Phase-contrast images showing SLIT1-releasing beads (blue-coloured) placed next to the bottom of attached OV, and corresponding immunohistochemistry for the axons of the RGCs by NFL staining. ( a,c ) The paths of the axons of hESC- and hiPSCs- derived RGCs (( a ) and ( c ), respectively) stained by NFL radiate straight from the attached OV, even though the bead is located close by. ( b , d ) Compared with the control, the axons of hESC- and hiPSC-derived RGCs (( b ) and ( d ), respectively) are repelled by SLIT1 release from the bead, and axonal paths are not straight, but winding, and avoid the beads. The assessment from D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Scale bars, 100 μm.

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: The effect of focally sustained release of SLIT1 on pathfinding of axons derived from hESC- and hiPSC-derived RGCs. Phase-contrast images showing SLIT1-releasing beads (blue-coloured) placed next to the bottom of attached OV, and corresponding immunohistochemistry for the axons of the RGCs by NFL staining. ( a,c ) The paths of the axons of hESC- and hiPSCs- derived RGCs (( a ) and ( c ), respectively) stained by NFL radiate straight from the attached OV, even though the bead is located close by. ( b , d ) Compared with the control, the axons of hESC- and hiPSC-derived RGCs (( b ) and ( d ), respectively) are repelled by SLIT1 release from the bead, and axonal paths are not straight, but winding, and avoid the beads. The assessment from D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Scale bars, 100 μm.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Immunohistochemistry, Staining, Control